BioAtla, Inc. (BCAB) Financials
BCAB Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-09-30 | 151.4 million | 56.7 million |
| 2023-06-30 | 179.6 million | 55.1 million |
| 2023-03-31 | 204.6 million | 48.1 million |
| 2022-12-31 | 225.7 million | 45.4 million |
BCAB Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-09-30 | -27.4 million | 3.5 million |
| 2023-06-30 | -24.1 million | 3.7 million |
| 2023-03-31 | -22.7 million | 3.6 million |
| 2022-12-31 | -24.4 million | 3.5 million |
BCAB Net Income
No data available :(
BCAB Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-09-30 | 141.3 million | - | 2.8 million |
| 2023-06-30 | 168.7 million | - | 3.2 million |
| 2023-03-31 | 192.7 million | - | 3.6 million |
| 2022-12-31 | 215.5 million | - | 4.0 million |
BCAB Shares Outstanding
BCAB Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-09-30 | 25000 | 28.4 million | 6.6 million | - |
| 2023-06-30 | 15000 | 31.0 million | 6.2 million | - |
| 2023-03-31 | 50000 | 21.7 million | 7.2 million | - |
| 2022-12-31 | 31000 | 21.9 million | 6.7 million | - |
BCAB Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-09-30 | - | 270000 |
| 2023-06-30 | - | 290000 |
| 2023-03-31 | - | 293000 |
| 2022-12-31 | - | 298000 |
BCAB
Price: $3.16
52 week price:
Earnings Per Share: -2.58 USD
P/E Ratio: -0.93
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 285700
Market Capitalization: 150.5 million